Search
Lancaster, PA Paid Clinical Trials
A listing of 64 clinical trials in Lancaster, PA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
49 - 60 of 64
There are currently 64 clinical trials in Lancaster, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including Lancaster General Hospital, Urological Associates Of Lancaster, Lancaster General Ann B. Barshinger Cancer Institute and Keystone Urology Specialists. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
Recruiting
This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The purpose of this study is to estimate rate of acute clinician-reported gastrointestinal (GI) toxicity using WP PBS PRT in the definitive treatment of gynecologic cancers in the post-surgical, adjuvant setting.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Lancaster General Health - Ann B. Barshinger Cancer Institute, Lancaster, Pennsylvania
Conditions: Cervical Cancer, Uterine Cancer, Endometrial Cancer
A PIVOTAL STUDY EVALUATING SAFETY and EFFICACY of the SHIRATRONICS MIGRAINE THERAPY SYSTEM
Recruiting
Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/04/2025
Locations: Argires Marotti Neurological Associates, Lancaster, Pennsylvania
Conditions: Headache Migraine Chronic
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
Recruiting
Multiple-dose study to measure pharmacokinetics, pharmacodynamics and safety of bempedoic acid in pediatric participants 6 to 17 years of age with HeFH.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
02/26/2025
Locations: Cardiology Care for Children, Lancaster, Pennsylvania
Conditions: Hypercholesterolemia
The Radiation Oncology Registry and Biosample Repository
Recruiting
The goal of this study is to establish a registry and biosample repository (defined as blood, urine, and tumor specimens) in patients with a cancer and/or benign tumor diagnosis undergoing radiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Neoplasia
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Recruiting
The main purpose of this study is to determine the safety of combining ipilimumab and nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic melanoma. Another purpose of this study is to determine the effect of ipilimumab, nivolumab and hypofractionated radiotherapy on the cancer as compared to ipilimumab and nivolumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Metastatic Melanoma
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Recruiting
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/06/2025
Locations: US Digestive Health at Lancaster, Lancaster, Pennsylvania
Conditions: Lung Cancer Diagnosis
Persona Revision Knee System Outcomes
Recruiting
The study will evaluate the performance, clinical benefits and safety of the Persona Revision Knee System in patients who have received primary or revision total knee arthroplasty (TKA) treatment. This will be done using a multicenter, single-arm, consecutive series, retrospective cohort study with prospective follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Penn Medicine/ Lancaster General Health, Lancaster, Pennsylvania
Conditions: Arthroplasty Complications, Infection, Knee Disease, Knee Osteoarthritis
Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
Recruiting
This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Dilated Cardiomyopathy, Heart Failure, Heart Disease
Cardiac Implantable Electronic Device (CIED) Research Study
Recruiting
The study is designed to collect data on Cardiovascular Implantable Electronic Device (CIED) information, implant procedure details, and/or patient characteristics to support development of future CIED products and procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/10/2025
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Arrhythmias, Cardiac, Bradycardia, Tachycardia
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
Recruiting
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
11/11/2024
Locations: Cardiology Care for Children, Lancaster, Pennsylvania
Conditions: Cardiomyopathy
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Recruiting
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
49 - 60 of 64